Phase 3 Pancreatic Cancer Trial, Recruiting NCT07087054 Sponsor: Crinetics Pharmaceuticals Inc. Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Phase 3 Pancreatic Cancer Trial, Recruiting

NCT07087054
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years of age or older at the time of screening
  • You are willing and able to follow all study procedures, including completing a study diary at least 70% of the time over a 2-week period
  • You have been diagnosed with carcinoid syndrome that needs medical treatment, and you experience flushing episodes (with or without frequent bowel movements) — specifically, more than 1 flushing episode per day on average over 14 days (either without current treatment, or during a washout period if coming off existing treatment)
  • You have confirmed advanced or metastatic well-differentiated neuroendocrine tumors (a type of slow-growing cancer) supported by documented test results
  • Your disease has not significantly worsened in the 6 months before joining the trial, as assessed by the study doctor

Who may not be able to join:

  • Your diarrhea is caused by something other than carcinoid syndrome
  • You have severe, uncontrolled diarrhea that has led to serious dehydration or low blood pressure
  • In your doctor's opinion, you need additional or second-line treatments to manage your carcinoid syndrome symptoms
  • You have received certain specific cancer treatments (such as everolimus or sunitinib) within 4 weeks before screening, or liver embolization, radiation therapy, targeted radiation (PRRT), or tumor removal surgery within 12 weeks before screening
  • You have had major surgery within 8 weeks before screening
  • You have had another type of cancer within the last 3 years (with some exceptions for certain treated skin cancers, fully removed breast cancer, cervical pre-cancer, or other cancers fully treated at least 3 years ago with no current signs of disease — confirm with trial site)
  • You have been using insulin to treat diabetes for less than 6 weeks before joining the study
  • You have poorly controlled diabetes, shown by a blood sugar control test result (HbA1c) of 8.5% or higher
  • You are unable to use short-acting octreotide injections, or you have previously tried somatostatin-type medications and they did not work for you
  • You have other significant health conditions not related to your primary diagnosis, such as serious heart disease, poor kidney function, or abnormal liver test results (confirm with trial site)
  • You currently use or abuse alcohol or drugs
  • You have been diagnosed with gallstones that are causing symptoms

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 8 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 833-276-4636

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Crinetics Pharmaceuticals Inc.
Registry
ClinicalTrials.gov
Start date
19 November 2025
Est. completion
1 August 2027

Where this trial is recruiting

🇦🇷 Argentina 🇧🇷 Brazil 🇨🇱 Chile 🇨🇴 Colombia 🇫🇷 France 🇲🇽 Mexico 🇪🇸 Spain 🇬🇧 United Kingdom 🇺🇸 United States

Primary endpoints

Participants will record the number of flushing per day in a daily diary to assess the efficacy of paltusotine vs placebo in reducing flushing episodes.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov